nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—AR—Ergocalciferol—osteoporosis	0.277	0.368	CbGbCtD
Nilutamide—AR—Estradiol—osteoporosis	0.144	0.191	CbGbCtD
Nilutamide—CYP2C9—Estropipate—osteoporosis	0.0529	0.0703	CbGbCtD
Nilutamide—CYP2C8—Raloxifene—osteoporosis	0.0506	0.0673	CbGbCtD
Nilutamide—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0489	0.065	CbGbCtD
Nilutamide—CYP2C8—Cholecalciferol—osteoporosis	0.0391	0.052	CbGbCtD
Nilutamide—CYP2C19—Cholecalciferol—osteoporosis	0.0328	0.0436	CbGbCtD
Nilutamide—CYP2C8—Estradiol—osteoporosis	0.0315	0.0419	CbGbCtD
Nilutamide—CYP2C9—Cholecalciferol—osteoporosis	0.0272	0.0362	CbGbCtD
Nilutamide—CYP2C19—Estradiol—osteoporosis	0.0264	0.0351	CbGbCtD
Nilutamide—CYP2C9—Estradiol—osteoporosis	0.022	0.0292	CbGbCtD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.00162	0.122	CbGpPWpGaD
Nilutamide—AR—Nongenotropic Androgen signaling—SHBG—osteoporosis	0.000984	0.0745	CbGpPWpGaD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000849	0.0643	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—GSN—osteoporosis	0.00051	0.0386	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—PARK7—osteoporosis	0.000377	0.0286	CbGpPWpGaD
Nilutamide—Pain—Ibandronate—osteoporosis	0.000375	0.00159	CcSEcCtD
Nilutamide—Constipation—Ibandronate—osteoporosis	0.000375	0.00159	CcSEcCtD
Nilutamide—Pruritus—Etidronic acid—osteoporosis	0.000374	0.00159	CcSEcCtD
Nilutamide—Gastrointestinal pain—Estropipate—osteoporosis	0.000374	0.00159	CcSEcCtD
Nilutamide—Decreased appetite—Calcitriol—osteoporosis	0.000373	0.00159	CcSEcCtD
Nilutamide—Back pain—Zoledronate—osteoporosis	0.000372	0.00158	CcSEcCtD
Nilutamide—Feeling abnormal—Alendronate—osteoporosis	0.000371	0.00158	CcSEcCtD
Nilutamide—Oedema—Ethinyl Estradiol—osteoporosis	0.000371	0.00158	CcSEcCtD
Nilutamide—Loss of consciousness—Pamidronate—osteoporosis	0.00037	0.00157	CcSEcCtD
Nilutamide—Dry mouth—Risedronate—osteoporosis	0.000369	0.00157	CcSEcCtD
Nilutamide—Urinary tract infection—Estradiol—osteoporosis	0.000369	0.00157	CcSEcCtD
Nilutamide—Gastrointestinal pain—Alendronate—osteoporosis	0.000368	0.00157	CcSEcCtD
Nilutamide—Cough—Pamidronate—osteoporosis	0.000367	0.00156	CcSEcCtD
Nilutamide—Pain—Calcitriol—osteoporosis	0.000367	0.00156	CcSEcCtD
Nilutamide—Constipation—Calcitriol—osteoporosis	0.000367	0.00156	CcSEcCtD
Nilutamide—Hypertension—Pamidronate—osteoporosis	0.000363	0.00155	CcSEcCtD
Nilutamide—Tension—Conjugated Estrogens—osteoporosis	0.000363	0.00155	CcSEcCtD
Nilutamide—Gastrointestinal pain—Raloxifene—osteoporosis	0.000362	0.00154	CcSEcCtD
Nilutamide—Diarrhoea—Etidronic acid—osteoporosis	0.000362	0.00154	CcSEcCtD
Nilutamide—Haematuria—Estradiol—osteoporosis	0.000361	0.00154	CcSEcCtD
Nilutamide—Body temperature increased—Estropipate—osteoporosis	0.000361	0.00154	CcSEcCtD
Nilutamide—Abdominal pain—Estropipate—osteoporosis	0.000361	0.00154	CcSEcCtD
Nilutamide—Feeling abnormal—Ibandronate—osteoporosis	0.000361	0.00154	CcSEcCtD
Nilutamide—Nervousness—Conjugated Estrogens—osteoporosis	0.00036	0.00153	CcSEcCtD
Nilutamide—Gastrointestinal pain—Ibandronate—osteoporosis	0.000359	0.00152	CcSEcCtD
Nilutamide—Back pain—Conjugated Estrogens—osteoporosis	0.000358	0.00152	CcSEcCtD
Nilutamide—Ill-defined disorder—Zoledronate—osteoporosis	0.000357	0.00152	CcSEcCtD
Nilutamide—Abdominal pain—Alendronate—osteoporosis	0.000356	0.00151	CcSEcCtD
Nilutamide—Body temperature increased—Alendronate—osteoporosis	0.000356	0.00151	CcSEcCtD
Nilutamide—Shock—Risedronate—osteoporosis	0.000355	0.00151	CcSEcCtD
Nilutamide—Anaemia—Zoledronate—osteoporosis	0.000355	0.00151	CcSEcCtD
Nilutamide—Discomfort—Pamidronate—osteoporosis	0.000354	0.00151	CcSEcCtD
Nilutamide—Gastrointestinal pain—Calcitriol—osteoporosis	0.000351	0.00149	CcSEcCtD
Nilutamide—Body temperature increased—Raloxifene—osteoporosis	0.00035	0.00149	CcSEcCtD
Nilutamide—Abdominal pain—Raloxifene—osteoporosis	0.00035	0.00149	CcSEcCtD
Nilutamide—Malaise—Zoledronate—osteoporosis	0.000347	0.00147	CcSEcCtD
Nilutamide—Abdominal pain—Ibandronate—osteoporosis	0.000347	0.00147	CcSEcCtD
Nilutamide—Body temperature increased—Ibandronate—osteoporosis	0.000347	0.00147	CcSEcCtD
Nilutamide—Syncope—Zoledronate—osteoporosis	0.000345	0.00147	CcSEcCtD
Nilutamide—Leukopenia—Zoledronate—osteoporosis	0.000344	0.00146	CcSEcCtD
Nilutamide—Oedema—Pamidronate—osteoporosis	0.000343	0.00146	CcSEcCtD
Nilutamide—Rhinitis—Estradiol—osteoporosis	0.000341	0.00145	CcSEcCtD
Nilutamide—Abdominal pain—Calcitriol—osteoporosis	0.000339	0.00144	CcSEcCtD
Nilutamide—Body temperature increased—Calcitriol—osteoporosis	0.000339	0.00144	CcSEcCtD
Nilutamide—Hypoaesthesia—Estradiol—osteoporosis	0.000339	0.00144	CcSEcCtD
Nilutamide—Shock—Pamidronate—osteoporosis	0.000338	0.00144	CcSEcCtD
Nilutamide—Loss of consciousness—Zoledronate—osteoporosis	0.000338	0.00144	CcSEcCtD
Nilutamide—Urinary tract disorder—Estradiol—osteoporosis	0.000336	0.00143	CcSEcCtD
Nilutamide—Vomiting—Etidronic acid—osteoporosis	0.000336	0.00143	CcSEcCtD
Nilutamide—Cough—Zoledronate—osteoporosis	0.000335	0.00143	CcSEcCtD
Nilutamide—Oedema peripheral—Estradiol—osteoporosis	0.000335	0.00143	CcSEcCtD
Nilutamide—Urethral disorder—Estradiol—osteoporosis	0.000334	0.00142	CcSEcCtD
Nilutamide—Rash—Etidronic acid—osteoporosis	0.000333	0.00142	CcSEcCtD
Nilutamide—Dermatitis—Etidronic acid—osteoporosis	0.000333	0.00142	CcSEcCtD
Nilutamide—Hyperhidrosis—Pamidronate—osteoporosis	0.000332	0.00141	CcSEcCtD
Nilutamide—Syncope—Conjugated Estrogens—osteoporosis	0.000332	0.00141	CcSEcCtD
Nilutamide—Hypertension—Zoledronate—osteoporosis	0.000332	0.00141	CcSEcCtD
Nilutamide—Headache—Etidronic acid—osteoporosis	0.000331	0.00141	CcSEcCtD
Nilutamide—Asthenia—Estropipate—osteoporosis	0.000328	0.0014	CcSEcCtD
Nilutamide—Visual impairment—Estradiol—osteoporosis	0.000328	0.00139	CcSEcCtD
Nilutamide—Anorexia—Pamidronate—osteoporosis	0.000327	0.00139	CcSEcCtD
Nilutamide—Chest pain—Zoledronate—osteoporosis	0.000327	0.00139	CcSEcCtD
Nilutamide—Insomnia—Risedronate—osteoporosis	0.000327	0.00139	CcSEcCtD
Nilutamide—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000325	0.00138	CcSEcCtD
Nilutamide—Paraesthesia—Risedronate—osteoporosis	0.000324	0.00138	CcSEcCtD
Nilutamide—AR—Notch-mediated HES/HEY network—BGLAP—osteoporosis	0.000324	0.0245	CbGpPWpGaD
Nilutamide—Pruritus—Estropipate—osteoporosis	0.000323	0.00138	CcSEcCtD
Nilutamide—Discomfort—Zoledronate—osteoporosis	0.000323	0.00138	CcSEcCtD
Nilutamide—Asthenia—Alendronate—osteoporosis	0.000323	0.00137	CcSEcCtD
Nilutamide—Cough—Conjugated Estrogens—osteoporosis	0.000323	0.00137	CcSEcCtD
Nilutamide—Dyspnoea—Risedronate—osteoporosis	0.000322	0.00137	CcSEcCtD
Nilutamide—Dry mouth—Zoledronate—osteoporosis	0.00032	0.00136	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00032	0.00136	CcSEcCtD
Nilutamide—Pruritus—Alendronate—osteoporosis	0.000319	0.00136	CcSEcCtD
Nilutamide—Dyspepsia—Risedronate—osteoporosis	0.000318	0.00135	CcSEcCtD
Nilutamide—Constipation—Ethinyl Estradiol—osteoporosis	0.000317	0.00135	CcSEcCtD
Nilutamide—Chest pain—Conjugated Estrogens—osteoporosis	0.000315	0.00134	CcSEcCtD
Nilutamide—Asthenia—Ibandronate—osteoporosis	0.000315	0.00134	CcSEcCtD
Nilutamide—Nausea—Etidronic acid—osteoporosis	0.000314	0.00134	CcSEcCtD
Nilutamide—Oedema—Zoledronate—osteoporosis	0.000314	0.00133	CcSEcCtD
Nilutamide—Diarrhoea—Estropipate—osteoporosis	0.000313	0.00133	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Risedronate—osteoporosis	0.000312	0.00133	CcSEcCtD
Nilutamide—Insomnia—Pamidronate—osteoporosis	0.000311	0.00132	CcSEcCtD
Nilutamide—Pruritus—Ibandronate—osteoporosis	0.00031	0.00132	CcSEcCtD
Nilutamide—Pain—Risedronate—osteoporosis	0.000309	0.00131	CcSEcCtD
Nilutamide—Constipation—Risedronate—osteoporosis	0.000309	0.00131	CcSEcCtD
Nilutamide—Shock—Zoledronate—osteoporosis	0.000309	0.00131	CcSEcCtD
Nilutamide—Paraesthesia—Pamidronate—osteoporosis	0.000308	0.00131	CcSEcCtD
Nilutamide—Diarrhoea—Alendronate—osteoporosis	0.000308	0.00131	CcSEcCtD
Nilutamide—Asthenia—Calcitriol—osteoporosis	0.000308	0.00131	CcSEcCtD
Nilutamide—AR—Nuclear Receptors—ESR2—osteoporosis	0.000307	0.0233	CbGpPWpGaD
Nilutamide—Dyspnoea—Pamidronate—osteoporosis	0.000306	0.0013	CcSEcCtD
Nilutamide—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000305	0.0013	CcSEcCtD
Nilutamide—Pruritus—Calcitriol—osteoporosis	0.000304	0.00129	CcSEcCtD
Nilutamide—Hyperhidrosis—Zoledronate—osteoporosis	0.000303	0.00129	CcSEcCtD
Nilutamide—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000303	0.00129	CcSEcCtD
Nilutamide—Diarrhoea—Raloxifene—osteoporosis	0.000303	0.00129	CcSEcCtD
Nilutamide—Dyspepsia—Pamidronate—osteoporosis	0.000302	0.00129	CcSEcCtD
Nilutamide—Dizziness—Estropipate—osteoporosis	0.000302	0.00129	CcSEcCtD
Nilutamide—Oedema—Conjugated Estrogens—osteoporosis	0.000302	0.00128	CcSEcCtD
Nilutamide—Alopecia—Estradiol—osteoporosis	0.000301	0.00128	CcSEcCtD
Nilutamide—Diarrhoea—Ibandronate—osteoporosis	0.0003	0.00128	CcSEcCtD
Nilutamide—Anorexia—Zoledronate—osteoporosis	0.000299	0.00127	CcSEcCtD
Nilutamide—Decreased appetite—Pamidronate—osteoporosis	0.000299	0.00127	CcSEcCtD
Nilutamide—Dizziness—Alendronate—osteoporosis	0.000298	0.00127	CcSEcCtD
Nilutamide—Shock—Conjugated Estrogens—osteoporosis	0.000297	0.00126	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000297	0.00126	CcSEcCtD
Nilutamide—Gastrointestinal pain—Risedronate—osteoporosis	0.000295	0.00126	CcSEcCtD
Nilutamide—Pain—Pamidronate—osteoporosis	0.000294	0.00125	CcSEcCtD
Nilutamide—Constipation—Pamidronate—osteoporosis	0.000294	0.00125	CcSEcCtD
Nilutamide—Diarrhoea—Calcitriol—osteoporosis	0.000294	0.00125	CcSEcCtD
Nilutamide—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000293	0.00125	CcSEcCtD
Nilutamide—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000293	0.00125	CcSEcCtD
Nilutamide—Dizziness—Raloxifene—osteoporosis	0.000293	0.00125	CcSEcCtD
Nilutamide—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000292	0.00124	CcSEcCtD
Nilutamide—Tension—Estradiol—osteoporosis	0.000291	0.00124	CcSEcCtD
Nilutamide—Vomiting—Estropipate—osteoporosis	0.000291	0.00124	CcSEcCtD
Nilutamide—Dizziness—Ibandronate—osteoporosis	0.00029	0.00123	CcSEcCtD
Nilutamide—Rash—Estropipate—osteoporosis	0.000288	0.00123	CcSEcCtD
Nilutamide—Dermatitis—Estropipate—osteoporosis	0.000288	0.00123	CcSEcCtD
Nilutamide—Anorexia—Conjugated Estrogens—osteoporosis	0.000288	0.00122	CcSEcCtD
Nilutamide—Nervousness—Estradiol—osteoporosis	0.000288	0.00122	CcSEcCtD
Nilutamide—Back pain—Estradiol—osteoporosis	0.000287	0.00122	CcSEcCtD
Nilutamide—Headache—Estropipate—osteoporosis	0.000286	0.00122	CcSEcCtD
Nilutamide—Vomiting—Alendronate—osteoporosis	0.000286	0.00122	CcSEcCtD
Nilutamide—Abdominal pain—Risedronate—osteoporosis	0.000286	0.00121	CcSEcCtD
Nilutamide—Body temperature increased—Risedronate—osteoporosis	0.000286	0.00121	CcSEcCtD
Nilutamide—Rash—Alendronate—osteoporosis	0.000284	0.00121	CcSEcCtD
Nilutamide—Insomnia—Zoledronate—osteoporosis	0.000284	0.00121	CcSEcCtD
Nilutamide—Dermatitis—Alendronate—osteoporosis	0.000284	0.00121	CcSEcCtD
Nilutamide—Feeling abnormal—Pamidronate—osteoporosis	0.000283	0.0012	CcSEcCtD
Nilutamide—Headache—Alendronate—osteoporosis	0.000282	0.0012	CcSEcCtD
Nilutamide—Paraesthesia—Zoledronate—osteoporosis	0.000282	0.0012	CcSEcCtD
Nilutamide—Vomiting—Raloxifene—osteoporosis	0.000282	0.0012	CcSEcCtD
Nilutamide—Gastrointestinal pain—Pamidronate—osteoporosis	0.000281	0.00119	CcSEcCtD
Nilutamide—Dyspnoea—Zoledronate—osteoporosis	0.00028	0.00119	CcSEcCtD
Nilutamide—Rash—Raloxifene—osteoporosis	0.000279	0.00119	CcSEcCtD
Nilutamide—Dermatitis—Raloxifene—osteoporosis	0.000279	0.00119	CcSEcCtD
Nilutamide—Vomiting—Ibandronate—osteoporosis	0.000279	0.00119	CcSEcCtD
Nilutamide—Headache—Raloxifene—osteoporosis	0.000277	0.00118	CcSEcCtD
Nilutamide—Rash—Ibandronate—osteoporosis	0.000276	0.00118	CcSEcCtD
Nilutamide—Dermatitis—Ibandronate—osteoporosis	0.000276	0.00117	CcSEcCtD
Nilutamide—Dyspepsia—Zoledronate—osteoporosis	0.000276	0.00117	CcSEcCtD
Nilutamide—Ill-defined disorder—Estradiol—osteoporosis	0.000275	0.00117	CcSEcCtD
Nilutamide—Headache—Ibandronate—osteoporosis	0.000275	0.00117	CcSEcCtD
Nilutamide—Insomnia—Conjugated Estrogens—osteoporosis	0.000273	0.00116	CcSEcCtD
Nilutamide—Vomiting—Calcitriol—osteoporosis	0.000273	0.00116	CcSEcCtD
Nilutamide—Decreased appetite—Zoledronate—osteoporosis	0.000273	0.00116	CcSEcCtD
Nilutamide—Nausea—Estropipate—osteoporosis	0.000272	0.00116	CcSEcCtD
Nilutamide—Abdominal pain—Pamidronate—osteoporosis	0.000272	0.00115	CcSEcCtD
Nilutamide—Body temperature increased—Pamidronate—osteoporosis	0.000272	0.00115	CcSEcCtD
Nilutamide—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000271	0.00115	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000271	0.00115	CcSEcCtD
Nilutamide—Rash—Calcitriol—osteoporosis	0.000271	0.00115	CcSEcCtD
Nilutamide—Dermatitis—Calcitriol—osteoporosis	0.00027	0.00115	CcSEcCtD
Nilutamide—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000269	0.00115	CcSEcCtD
Nilutamide—Headache—Calcitriol—osteoporosis	0.000269	0.00114	CcSEcCtD
Nilutamide—Pain—Zoledronate—osteoporosis	0.000268	0.00114	CcSEcCtD
Nilutamide—Constipation—Zoledronate—osteoporosis	0.000268	0.00114	CcSEcCtD
Nilutamide—Nausea—Alendronate—osteoporosis	0.000267	0.00114	CcSEcCtD
Nilutamide—Malaise—Estradiol—osteoporosis	0.000267	0.00114	CcSEcCtD
Nilutamide—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000266	0.00113	CcSEcCtD
Nilutamide—Asthenia—Ethinyl Estradiol—osteoporosis	0.000266	0.00113	CcSEcCtD
Nilutamide—Syncope—Estradiol—osteoporosis	0.000266	0.00113	CcSEcCtD
Nilutamide—Nausea—Raloxifene—osteoporosis	0.000263	0.00112	CcSEcCtD
Nilutamide—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000263	0.00112	CcSEcCtD
Nilutamide—Pruritus—Ethinyl Estradiol—osteoporosis	0.000262	0.00112	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000261	0.00111	CcSEcCtD
Nilutamide—Nausea—Ibandronate—osteoporosis	0.00026	0.00111	CcSEcCtD
Nilutamide—Loss of consciousness—Estradiol—osteoporosis	0.00026	0.00111	CcSEcCtD
Nilutamide—Asthenia—Risedronate—osteoporosis	0.000259	0.0011	CcSEcCtD
Nilutamide—Feeling abnormal—Zoledronate—osteoporosis	0.000259	0.0011	CcSEcCtD
Nilutamide—Cough—Estradiol—osteoporosis	0.000259	0.0011	CcSEcCtD
Nilutamide—Pain—Conjugated Estrogens—osteoporosis	0.000258	0.0011	CcSEcCtD
Nilutamide—Constipation—Conjugated Estrogens—osteoporosis	0.000258	0.0011	CcSEcCtD
Nilutamide—Gastrointestinal pain—Zoledronate—osteoporosis	0.000257	0.00109	CcSEcCtD
Nilutamide—Hypertension—Estradiol—osteoporosis	0.000256	0.00109	CcSEcCtD
Nilutamide—Pruritus—Risedronate—osteoporosis	0.000256	0.00109	CcSEcCtD
Nilutamide—Nausea—Calcitriol—osteoporosis	0.000255	0.00108	CcSEcCtD
Nilutamide—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000254	0.00108	CcSEcCtD
Nilutamide—Chest pain—Estradiol—osteoporosis	0.000252	0.00107	CcSEcCtD
Nilutamide—Discomfort—Estradiol—osteoporosis	0.000249	0.00106	CcSEcCtD
Nilutamide—Body temperature increased—Zoledronate—osteoporosis	0.000248	0.00105	CcSEcCtD
Nilutamide—Abdominal pain—Zoledronate—osteoporosis	0.000248	0.00105	CcSEcCtD
Nilutamide—Diarrhoea—Risedronate—osteoporosis	0.000247	0.00105	CcSEcCtD
Nilutamide—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000247	0.00105	CcSEcCtD
Nilutamide—Dry mouth—Estradiol—osteoporosis	0.000247	0.00105	CcSEcCtD
Nilutamide—Asthenia—Pamidronate—osteoporosis	0.000246	0.00105	CcSEcCtD
Nilutamide—Dizziness—Ethinyl Estradiol—osteoporosis	0.000245	0.00104	CcSEcCtD
Nilutamide—AR—Nuclear Receptors—VDR—osteoporosis	0.000244	0.0185	CbGpPWpGaD
Nilutamide—Pruritus—Pamidronate—osteoporosis	0.000243	0.00103	CcSEcCtD
Nilutamide—AR—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.000243	0.0184	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—COL1A2—osteoporosis	0.000242	0.0183	CbGpPWpGaD
Nilutamide—Oedema—Estradiol—osteoporosis	0.000242	0.00103	CcSEcCtD
Nilutamide—Dizziness—Risedronate—osteoporosis	0.000239	0.00102	CcSEcCtD
Nilutamide—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000239	0.00102	CcSEcCtD
Nilutamide—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000239	0.00102	CcSEcCtD
Nilutamide—Shock—Estradiol—osteoporosis	0.000238	0.00101	CcSEcCtD
Nilutamide—Vomiting—Ethinyl Estradiol—osteoporosis	0.000236	0.001	CcSEcCtD
Nilutamide—Diarrhoea—Pamidronate—osteoporosis	0.000235	0.001	CcSEcCtD
Nilutamide—Hyperhidrosis—Estradiol—osteoporosis	0.000234	0.000994	CcSEcCtD
Nilutamide—Rash—Ethinyl Estradiol—osteoporosis	0.000234	0.000994	CcSEcCtD
Nilutamide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000233	0.000993	CcSEcCtD
Nilutamide—Headache—Ethinyl Estradiol—osteoporosis	0.000232	0.000987	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—DKK1—osteoporosis	0.00023	0.0174	CbGpPWpGaD
Nilutamide—Vomiting—Risedronate—osteoporosis	0.00023	0.000977	CcSEcCtD
Nilutamide—Rash—Risedronate—osteoporosis	0.000228	0.000969	CcSEcCtD
Nilutamide—Dermatitis—Risedronate—osteoporosis	0.000228	0.000968	CcSEcCtD
Nilutamide—Dizziness—Pamidronate—osteoporosis	0.000227	0.000966	CcSEcCtD
Nilutamide—Headache—Risedronate—osteoporosis	0.000226	0.000963	CcSEcCtD
Nilutamide—Asthenia—Zoledronate—osteoporosis	0.000225	0.000957	CcSEcCtD
Nilutamide—Pruritus—Zoledronate—osteoporosis	0.000222	0.000944	CcSEcCtD
Nilutamide—Nausea—Ethinyl Estradiol—osteoporosis	0.00022	0.000936	CcSEcCtD
Nilutamide—Insomnia—Estradiol—osteoporosis	0.000219	0.00093	CcSEcCtD
Nilutamide—Vomiting—Pamidronate—osteoporosis	0.000218	0.000929	CcSEcCtD
Nilutamide—Paraesthesia—Estradiol—osteoporosis	0.000217	0.000923	CcSEcCtD
Nilutamide—Asthenia—Conjugated Estrogens—osteoporosis	0.000217	0.000922	CcSEcCtD
Nilutamide—Rash—Pamidronate—osteoporosis	0.000217	0.000921	CcSEcCtD
Nilutamide—Dermatitis—Pamidronate—osteoporosis	0.000216	0.00092	CcSEcCtD
Nilutamide—Dyspnoea—Estradiol—osteoporosis	0.000216	0.000917	CcSEcCtD
Nilutamide—Headache—Pamidronate—osteoporosis	0.000215	0.000915	CcSEcCtD
Nilutamide—Diarrhoea—Zoledronate—osteoporosis	0.000215	0.000913	CcSEcCtD
Nilutamide—Nausea—Risedronate—osteoporosis	0.000215	0.000913	CcSEcCtD
Nilutamide—Pruritus—Conjugated Estrogens—osteoporosis	0.000214	0.000909	CcSEcCtD
Nilutamide—Dyspepsia—Estradiol—osteoporosis	0.000213	0.000905	CcSEcCtD
Nilutamide—Decreased appetite—Estradiol—osteoporosis	0.00021	0.000894	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Estradiol—osteoporosis	0.000209	0.000888	CcSEcCtD
Nilutamide—Dizziness—Zoledronate—osteoporosis	0.000207	0.000882	CcSEcCtD
Nilutamide—Pain—Estradiol—osteoporosis	0.000207	0.000879	CcSEcCtD
Nilutamide—Constipation—Estradiol—osteoporosis	0.000207	0.000879	CcSEcCtD
Nilutamide—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000207	0.000879	CcSEcCtD
Nilutamide—Nausea—Pamidronate—osteoporosis	0.000204	0.000868	CcSEcCtD
Nilutamide—Dizziness—Conjugated Estrogens—osteoporosis	0.0002	0.00085	CcSEcCtD
Nilutamide—Vomiting—Zoledronate—osteoporosis	0.000199	0.000848	CcSEcCtD
Nilutamide—Feeling abnormal—Estradiol—osteoporosis	0.000199	0.000847	CcSEcCtD
Nilutamide—Rash—Zoledronate—osteoporosis	0.000198	0.000841	CcSEcCtD
Nilutamide—Gastrointestinal pain—Estradiol—osteoporosis	0.000198	0.000841	CcSEcCtD
Nilutamide—Dermatitis—Zoledronate—osteoporosis	0.000198	0.000841	CcSEcCtD
Nilutamide—Headache—Zoledronate—osteoporosis	0.000197	0.000836	CcSEcCtD
Nilutamide—AR—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.000193	0.0146	CbGpPWpGaD
Nilutamide—Vomiting—Conjugated Estrogens—osteoporosis	0.000192	0.000817	CcSEcCtD
Nilutamide—Abdominal pain—Estradiol—osteoporosis	0.000191	0.000813	CcSEcCtD
Nilutamide—Body temperature increased—Estradiol—osteoporosis	0.000191	0.000813	CcSEcCtD
Nilutamide—Rash—Conjugated Estrogens—osteoporosis	0.00019	0.00081	CcSEcCtD
Nilutamide—Dermatitis—Conjugated Estrogens—osteoporosis	0.00019	0.000809	CcSEcCtD
Nilutamide—Headache—Conjugated Estrogens—osteoporosis	0.000189	0.000805	CcSEcCtD
Nilutamide—Nausea—Zoledronate—osteoporosis	0.000186	0.000793	CcSEcCtD
Nilutamide—AR—Nuclear Receptors—ESR1—osteoporosis	0.000186	0.0141	CbGpPWpGaD
Nilutamide—Nausea—Conjugated Estrogens—osteoporosis	0.000179	0.000763	CcSEcCtD
Nilutamide—Asthenia—Estradiol—osteoporosis	0.000173	0.000738	CcSEcCtD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000172	0.0131	CbGpPWpGaD
Nilutamide—Pruritus—Estradiol—osteoporosis	0.000171	0.000728	CcSEcCtD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.00017	0.0129	CbGpPWpGaD
Nilutamide—AR—FOXA1 transcription factor network—ESR1—osteoporosis	0.000166	0.0125	CbGpPWpGaD
Nilutamide—Diarrhoea—Estradiol—osteoporosis	0.000165	0.000704	CcSEcCtD
Nilutamide—Dizziness—Estradiol—osteoporosis	0.00016	0.00068	CcSEcCtD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000154	0.0117	CbGpPWpGaD
Nilutamide—Vomiting—Estradiol—osteoporosis	0.000154	0.000654	CcSEcCtD
Nilutamide—Rash—Estradiol—osteoporosis	0.000152	0.000648	CcSEcCtD
Nilutamide—Dermatitis—Estradiol—osteoporosis	0.000152	0.000648	CcSEcCtD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000152	0.0115	CbGpPWpGaD
Nilutamide—Headache—Estradiol—osteoporosis	0.000151	0.000644	CcSEcCtD
Nilutamide—AR—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.000147	0.0111	CbGpPWpGaD
Nilutamide—Nausea—Estradiol—osteoporosis	0.000144	0.000611	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.000143	0.0108	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—RAP1A—osteoporosis	0.000143	0.0108	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.00014	0.0106	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.00014	0.0106	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000138	0.0105	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—VDR—osteoporosis	0.000133	0.0101	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000125	0.00944	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000119	0.00898	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000114	0.00861	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—osteoporosis	0.000102	0.0077	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000101	0.00768	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—ESR2—osteoporosis	9.92e-05	0.00752	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CYP19A1—osteoporosis	9.25e-05	0.007	CbGpPWpGaD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	9.05e-05	0.00686	CbGpPWpGaD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	8.93e-05	0.00677	CbGpPWpGaD
Nilutamide—CYP2C8—Arachidonic acid metabolism—GPX1—osteoporosis	8.53e-05	0.00646	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	8.44e-05	0.00639	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	8.08e-05	0.00612	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	7.97e-05	0.00604	CbGpPWpGaD
Nilutamide—CYP2C19—Arachidonic acid metabolism—GPX1—osteoporosis	7.61e-05	0.00577	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP27A1—osteoporosis	7.42e-05	0.00562	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	7.37e-05	0.00558	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	7.34e-05	0.00556	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP27A1—osteoporosis	7.32e-05	0.00554	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	7.27e-05	0.00551	CbGpPWpGaD
Nilutamide—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	6.94e-05	0.00526	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP27A1—osteoporosis	6.62e-05	0.00502	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	6.55e-05	0.00496	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP27A1—osteoporosis	6.53e-05	0.00495	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—ESR1—osteoporosis	6.18e-05	0.00468	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	6.04e-05	0.00457	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	5.97e-05	0.00452	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	5.96e-05	0.00451	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—IRS1—osteoporosis	5.77e-05	0.00437	CbGpPWpGaD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	5.44e-05	0.00412	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—osteoporosis	5.34e-05	0.00404	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—osteoporosis	5.29e-05	0.004	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL6R—osteoporosis	5.28e-05	0.004	CbGpPWpGaD
Nilutamide—AR—Gene Expression—U2AF1—osteoporosis	5.27e-05	0.00399	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	5.12e-05	0.00388	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	4.96e-05	0.00376	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	4.86e-05	0.00368	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	4.7e-05	0.00356	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	4.43e-05	0.00336	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	4.43e-05	0.00335	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	4.43e-05	0.00335	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—POMC—osteoporosis	4.41e-05	0.00334	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	4.2e-05	0.00318	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—ESR2—osteoporosis	4.19e-05	0.00318	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	4.04e-05	0.00306	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL1B—osteoporosis	4.02e-05	0.00304	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—osteoporosis	3.94e-05	0.00298	CbGpPWpGaD
Nilutamide—AR—Gene Expression—RPL24—osteoporosis	3.91e-05	0.00296	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP19A1—osteoporosis	3.9e-05	0.00295	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP19A1—osteoporosis	3.84e-05	0.00291	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	3.83e-05	0.0029	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	3.66e-05	0.00277	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	3.59e-05	0.00272	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	3.56e-05	0.0027	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP19A1—osteoporosis	3.48e-05	0.00264	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP19A1—osteoporosis	3.43e-05	0.0026	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—VDR—osteoporosis	3.33e-05	0.00252	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	3.26e-05	0.00247	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MYC—osteoporosis	3.21e-05	0.00243	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	3.18e-05	0.00241	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	3.17e-05	0.0024	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	3.13e-05	0.00237	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	2.98e-05	0.00225	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—TNF—osteoporosis	2.92e-05	0.00221	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	2.9e-05	0.0022	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	2.85e-05	0.00216	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.66e-05	0.00202	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.66e-05	0.00201	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	2.54e-05	0.00193	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—ESR1—osteoporosis	2.54e-05	0.00193	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	2.48e-05	0.00188	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	2.42e-05	0.00184	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL6—osteoporosis	2.35e-05	0.00178	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—POMC—osteoporosis	2.34e-05	0.00177	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	2.32e-05	0.00176	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PSMA2—osteoporosis	2.26e-05	0.00171	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PSMA5—osteoporosis	2.26e-05	0.00171	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—FDPS—osteoporosis	2.21e-05	0.00167	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PKM—osteoporosis	2.21e-05	0.00167	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	2.16e-05	0.00164	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GPD2—osteoporosis	2.09e-05	0.00159	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PGLS—osteoporosis	2.09e-05	0.00159	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—POMC—osteoporosis	2.09e-05	0.00158	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ESR2—osteoporosis	2.02e-05	0.00153	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—FDPS—osteoporosis	1.97e-05	0.00149	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PKM—osteoporosis	1.97e-05	0.00149	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	1.97e-05	0.00149	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ATIC—osteoporosis	1.92e-05	0.00145	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PNP—osteoporosis	1.92e-05	0.00145	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—POMC—osteoporosis	1.91e-05	0.00144	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PGLS—osteoporosis	1.87e-05	0.00142	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GPD2—osteoporosis	1.87e-05	0.00142	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—FDPS—osteoporosis	1.8e-05	0.00136	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PKM—osteoporosis	1.8e-05	0.00136	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PNP—osteoporosis	1.71e-05	0.0013	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ATIC—osteoporosis	1.71e-05	0.0013	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GPD2—osteoporosis	1.7e-05	0.00129	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PGLS—osteoporosis	1.7e-05	0.00129	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—OXCT1—osteoporosis	1.63e-05	0.00123	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CA2—osteoporosis	1.63e-05	0.00123	CbGpPWpGaD
Nilutamide—AR—Gene Expression—VDR—osteoporosis	1.6e-05	0.00121	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—MGLL—osteoporosis	1.59e-05	0.0012	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PNP—osteoporosis	1.56e-05	0.00118	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ATIC—osteoporosis	1.56e-05	0.00118	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.5e-05	0.00113	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—OXCT1—osteoporosis	1.45e-05	0.0011	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CA2—osteoporosis	1.45e-05	0.0011	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—MGLL—osteoporosis	1.42e-05	0.00107	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—IDH2—osteoporosis	1.35e-05	0.00102	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.34e-05	0.00101	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—OXCT1—osteoporosis	1.33e-05	0.001	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CA2—osteoporosis	1.33e-05	0.001	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—MYC—osteoporosis	1.32e-05	0.001	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—MGLL—osteoporosis	1.29e-05	0.000979	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP27A1—osteoporosis	1.27e-05	0.000961	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ACP5—osteoporosis	1.23e-05	0.000935	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ESR1—osteoporosis	1.22e-05	0.000927	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.22e-05	0.000923	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.22e-05	0.000923	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—IDH2—osteoporosis	1.2e-05	0.000913	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—TPI1—osteoporosis	1.15e-05	0.000869	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP27A1—osteoporosis	1.13e-05	0.000858	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ACP5—osteoporosis	1.1e-05	0.000835	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—IDH2—osteoporosis	1.1e-05	0.000832	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.09e-05	0.000824	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—P4HB—osteoporosis	1.08e-05	0.000817	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GAPDH—osteoporosis	1.06e-05	0.000802	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP27A1—osteoporosis	1.03e-05	0.000782	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—RAP1A—osteoporosis	1.03e-05	0.000781	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—TPI1—osteoporosis	1.02e-05	0.000776	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ACP5—osteoporosis	1e-05	0.000761	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	9.92e-06	0.000751	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—P4HB—osteoporosis	9.63e-06	0.00073	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GAPDH—osteoporosis	9.45e-06	0.000716	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—TPI1—osteoporosis	9.34e-06	0.000708	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—RAP1A—osteoporosis	9.21e-06	0.000697	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	9e-06	0.000681	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—P4HB—osteoporosis	8.78e-06	0.000665	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GAPDH—osteoporosis	8.62e-06	0.000653	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—RAP1A—osteoporosis	8.4e-06	0.000636	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ENO1—osteoporosis	8.34e-06	0.000632	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PSMA2—osteoporosis	8.22e-06	0.000622	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PSMA5—osteoporosis	8.22e-06	0.000622	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	8.03e-06	0.000608	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ENO1—osteoporosis	7.44e-06	0.000564	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PSMA2—osteoporosis	7.33e-06	0.000556	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PSMA5—osteoporosis	7.33e-06	0.000556	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	7.32e-06	0.000555	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ENO1—osteoporosis	6.79e-06	0.000514	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PSMA2—osteoporosis	6.69e-06	0.000507	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PSMA5—osteoporosis	6.69e-06	0.000507	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP19A1—osteoporosis	6.67e-06	0.000505	CbGpPWpGaD
Nilutamide—AR—Gene Expression—MYC—osteoporosis	6.37e-06	0.000482	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP19A1—osteoporosis	5.95e-06	0.000451	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ADCY5—osteoporosis	5.45e-06	0.000413	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GPX1—osteoporosis	5.43e-06	0.000411	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP19A1—osteoporosis	5.43e-06	0.000411	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—MTHFR—osteoporosis	5.01e-06	0.000379	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ADCY5—osteoporosis	4.86e-06	0.000368	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GPX1—osteoporosis	4.84e-06	0.000367	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—MTHFR—osteoporosis	4.47e-06	0.000339	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ADCY5—osteoporosis	4.43e-06	0.000336	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GPX1—osteoporosis	4.42e-06	0.000335	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—MTHFR—osteoporosis	4.08e-06	0.000309	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—POMC—osteoporosis	4.01e-06	0.000303	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—POMC—osteoporosis	3.58e-06	0.000271	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—POMC—osteoporosis	3.26e-06	0.000247	CbGpPWpGaD
